InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,618.80
(
0.05%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.56
(
-0.37%
)
Bitcoin
62,473.61
(
0.22%
)
Post# of 244
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

PENNIEStoSTACKS

Send PM Follow Ignore
Followers 1520
Posts 89014
Boards Moderated 5
Alias Born 05/09/2004

PENNIEStoSTACKS

Re: PENNIEStoSTACKS post# 5

Thursday, 12/27/2018 10:47:27 AM

Thursday, December 27, 2018 10:47:27 AM

Post# of 244
"(NASDAQ:ADIL; ADILW), www.adialpharma.com, a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced plans to expand activities around the Company’s lead asset, AD04, beyond alcohol use disorder (AUD), to now include its potential use in patients with opioid use disorder.
William Stilley, CEO of Adial Pharmaceuticals, said, “We are expanding our activities around AD04 to include opioid use disorder (OUD) and believe this program has significant potential since the physiology and neuro-transmitters involved in opioid addiction are similar to alcohol and could be expected to be modulated by a serotonin-3 receptor antagonist.”
https://ih.advfn.com/stock-market/NASDAQ/adial-pharmaceuticals-inc-ADIL/stock-news/78881798/adial-pharmaceuticals-announces-planned-expansion
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent ADIL News
More ADIL News
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!